{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Highly-sensitized+Kidney+Transplant+Recipients",
    "query": {
      "condition": "Highly-sensitized Kidney Transplant Recipients"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 6,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T00:16:39.362Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00407160",
      "title": "A Trial of Tolerogenic Immunosuppression in Highly Sensitized Renal Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Kidney Diseases"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 21,
      "start_date": "2004-08",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2019-03-04",
      "last_synced_at": "2026-07-23T00:16:39.362Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00407160"
    },
    {
      "nct_id": "NCT01911546",
      "title": "Role of Everolimus in Highly Sensitized Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Highly-sensitized Kidney Transplant Recipients"
      ],
      "interventions": [
        {
          "name": "everolimus + low-dose tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Joseph Kahwaji, MD, MPH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2013-06",
      "completion_date": "2016-01-19",
      "has_results": true,
      "last_update_posted_date": "2017-12-07",
      "last_synced_at": "2026-07-23T00:16:39.362Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01911546"
    },
    {
      "nct_id": "NCT04827979",
      "title": "Daratumumab and Belatacept for Desensitization",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Highly Sensitized Prospective Kidney Transplant Recipients"
      ],
      "interventions": [
        {
          "name": "daratumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "belatacept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bone marrow aspiration",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 19,
      "start_date": "2021-11-01",
      "completion_date": "2028-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-07-23T00:16:39.362Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04827979"
    },
    {
      "nct_id": "NCT00090194",
      "title": "Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Failure, Chronic"
      ],
      "interventions": [
        {
          "name": "Immune Globulin Intravenous (Human), 10%",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "1 Year to 70 Years"
      },
      "enrollment_count": 56,
      "start_date": "2003-06",
      "completion_date": "2004-03",
      "has_results": false,
      "last_update_posted_date": "2017-01-11",
      "last_synced_at": "2026-07-23T00:16:39.362Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00090194"
    },
    {
      "nct_id": "NCT05017545",
      "title": "Carfilzomib and Belatacept for Desensitization",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Highly Sensitized Prospective Kidney Transplant Recipients"
      ],
      "interventions": [
        {
          "name": "carfilzomib",
          "type": "BIOLOGICAL"
        },
        {
          "name": "belatacept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bone marrow aspiration",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 21,
      "start_date": "2021-12-28",
      "completion_date": "2028-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-07-23T00:16:39.362Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05017545"
    },
    {
      "nct_id": "NCT03194321",
      "title": "Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Tacrolimus Extended-Release Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2017-09-11",
      "completion_date": "2020-10-27",
      "has_results": true,
      "last_update_posted_date": "2022-01-19",
      "last_synced_at": "2026-07-23T00:16:39.362Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03194321"
    }
  ]
}